omniture
logo
Search

WuXi PharmaTech Statement on Recent News Report

WuXi PharmaTech
2015-01-05 21:00 1808

SHANGHAI, January 5, 2015 /PRNewswire/ -- WuXi PharmaTech stated today that a recent news report regarding purported FDA communication with a company named Novacyl Wuxi Pharmaceutical does not relate to WuXi PharmaTech.

Ron Aldridge
Director of Investor Relations
WuXi PharmaTech
+1 201-585-2048
+1 952-594-0148 (U.S.)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-statement-on-recent-news-report-300015312.html

Source: WuXi PharmaTech
Media Room more

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

2024-03-18 20:32
1970

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

2024-02-20 21:00
2758
WuXi Advanced Therapies 55,000 square foot commercial non-viral cell therapy manufacturing site, Commerce Center 3 (CC3), located in Philadelphia, PA, United States

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

2024-01-08 22:00
4529
New API Manufacturing Site at Taixing, Jiangsu, China

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

2023-11-09 08:00
1546

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

2023-10-30 20:01
2068

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

2023-07-31 18:02
3738
Related News

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

2024-04-26 21:00
714

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

2024-04-26 21:00
722

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

2024-04-26 12:39
750

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

2024-04-26 01:25
842

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

2024-04-25 22:00
731

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

2024-04-25 21:41
891
collection